VRM
TGTX icon

Vectors Research Management’s TG Therapeutics TGTX Stock Holding History

Vectors Research Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed – – 446
2022
Q2 		$0 Hold
100
– – ﹤0.01% 529
2022
Q1 		$1K Hold
100
– – ﹤0.01% 456
2021
Q4 		$2K Buy
+100
New +$2.6K ﹤0.01% 563

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vectors Research Management's TGTX Position: Q3 2022 in Review

Vectors Research Management sold out of TG Therapeutics (TGTX) in Q3 2022, closing a stake of 100 shares.

Vectors Research Management first reported a position in TGTX in Q4 2021 and held it in 3 quarters. The position peaked at $2K in Q4 2021. 183 funds tracked by Wall St. Rank hold TGTX as of Q3 2022.

  • Vectors Research Management reported no remaining TG Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Vectors Research Management sold 100 TG Therapeutics shares in Q3 2022.
  • Vectors Research Management first reported a position in TG Therapeutics in Q4 2021 and held it in 3 quarters.
  • Vectors Research Management's TG Therapeutics position peaked at $2K in Q4 2021.
  • 183 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.